Division of Hematology, Mayo Clinic, Rochester, MN.
Blood. 2013 Oct 3;122(14):2305-9. doi: 10.1182/blood-2013-05-484782. Epub 2013 Aug 23.
This spotlight review focuses on the second-generation immunomodulatory drug pomalidomide, which was recently approved by the US Food and Drug Administration. This drug was approved for patients with multiple myeloma who have received at least 2 prior therapies, including lenalidomide and bortezomib, and have demonstrated disease progression on or within 60 days of completion of the last therapy. This review focuses on the clinical trial data that led to approval and provides advice for treating physicians who are now prescribing this drug for patients.
本重点综述聚焦于第二代免疫调节药物泊马度胺，该药最近获得美国食品药品监督管理局批准。该药物获批用于至少接受过 2 种既往治疗的多发性骨髓瘤患者，包括来那度胺和硼替佐米，并且在上次治疗完成后 60 天内或治疗期间疾病进展。本综述重点介绍了支持批准的临床试验数据，并为目前为患者开具该药的治疗医师提供建议。
